Rachmiel M, Charron M, Gupta A, Hamilton J, Wherrett D, Forte V, Daneman D
Division of Endocrinology, Hospital for Sick Children, Toronto, Canada.
J Pediatr Endocrinol Metab. 2006 Dec;19(12):1377-93. doi: 10.1515/jpem.2006.19.12.1377.
Childhood onset differentiated thyroid cancer (DTC) is distinct from the adult-onset disease being more aggressive at the time of initial evaluation with a higher risk category for disease recurrence; however, it is ultimately less lethal. International groups have outlined consensus statements detailing follow up and management guidelines for adult DTC, but since disease progression and markers are significantly different in childhood DTC compared to adults, management protocols may differ. Unfortunately, there is no consensus regarding the means of follow up, timing and management strategy regarding pediatric DTC. We performed an evidence-based review of DTC in children targeted to address the following questions: What is the most appropriate initial treatment? What is the goal of thyroid hormone replacement management? What is the approach to follow-up of childhood DTC? and, How should tumor recurrence/persistence be assessed and treated? We conducted a literature search using PubMed, Cochrane databases, guidelines from various international groups, and studies pertaining to pediatric DTC management and outcome in order to answer these questions. We suggest a pre-set algorithm and approach for the management of children with DTC according to our review.
儿童期发病的分化型甲状腺癌(DTC)与成人期发病的疾病不同,在初次评估时更具侵袭性,疾病复发风险类别更高;然而,其最终致死率较低。国际组织已概述了详细的成人DTC随访和管理指南共识声明,但由于儿童DTC与成人相比疾病进展和标志物有显著差异,管理方案可能不同。不幸的是,关于儿童DTC的随访方式、时间和管理策略尚无共识。我们针对儿童DTC进行了基于证据的综述,以解决以下问题:最合适的初始治疗方法是什么?甲状腺激素替代治疗管理的目标是什么?儿童DTC的随访方法是什么?以及,应如何评估和治疗肿瘤复发/持续存在?我们使用PubMed、Cochrane数据库、各国际组织的指南以及与儿童DTC管理和结局相关的研究进行文献检索,以回答这些问题。根据我们的综述,我们建议采用预先设定的算法和方法来管理儿童DTC。